This study explores the therapeutic effect of the combination of BRAF and MEK inhibitors (BRAFi + MEKi) on NRAS-mutated melanomas in vitro, in preclinical in vivo models using patient-derived xenografts (PDXs) and in an individual healing attempt of one patient. Here, BRAF is linked to melanoma.